Accepted Manuscript

How effectively will PCSK9 inhibitors allow restoration of freedom from apheresis in cardiovascular high risk patients? – Estimates form a large single center


Bernd Hohenstein, Sergey Tselmin, Stefan R. Bornstein, Ulrich Julius

PII: \$1567-5688(17)30054-5


DOI: 10.1016/j.atherosclerosissup.2017.05.012

Reference: ATHSUP 304

To appear in: Atherosclerosis (Supplements) (Component)



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

How effectively will PCSK9 inhibitors allow restoration of freedom from apheresis in cardiovascular high risk patients? – Estimates form a large single center

Bernd Hohenstein, Sergey Tselmin, Stefan R. Bornstein, and Ulrich Julius

Extracorporeal Treatment and Apheresis Center, Department of Internal Medicine, University

Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden,

Germany

Corresponding author

Prof. Dr. Bernd Hohenstein

Extracorporeal Treatment and Apheresis Center

Department of Internal Medicine

University Hospital and Faculty of Medicine Carl Gustav Carus

Technische Universität Dresden

Fetscherstraße 74

01307 Dresden, Germany

Phone: +49 351 458 3075

Fax: +49 351 458 5333

bernd.hohenstein@uniklinkum-dresden.de

Keywords: lipoprotein apheresis, lipids, PCSK9, lipoprotein(a), LDL-cholesterol

Download English Version:

https://daneshyari.com/en/article/8657249

Download Persian Version:

https://daneshyari.com/article/8657249

<u>Daneshyari.com</u>